Nurix Therapeutics chief scientific officer Gwenn Hansen reports disposal of $142,900.9987 in common shares
NRIX•Gwenn Hansen sold 3,957 Nurix Therapeutics common shares at $26.2791 on Oct. 30, 2026, and exercised options for 1,452 shares at $1.86 on Nov. 2, selling those shares at $26.80. She also acquired 10,182 shares through restricted stock unit conversions and held 123,452 shares directly after the transactions.
1. Hansen’s share transactions
Nurix Therapeutics Chief Scientific Officer Gwenn Hansen sold 3,957 common shares at $26.2791 on Oct. 30, 2026, and acquired 10,182 common shares at no cost through restricted stock unit conversions that day. On Nov. 2, she exercised options for 1,452 shares at $1.86 and sold those shares at $26.80; her direct beneficial ownership after the transactions was 123,452 common shares.
